Related stories
FDA Approves Bayer’s SUNHARBO for Stroke-Risk Reduction
The FDA approved Bayer’s asundexian 50 mg tablets, in combination with antiplatelet therapy, to reduce stroke risk in adults with recent non-cardioembolic ischemic stroke or high-r
M impact | REGULATION | Nov 10, 2026, 01:11 AM UTC
Australia PM Albanese Announces Mandatory AI Safety And Security Protections
New Dedicated AI Safety Regulator To Oversee Protections
L impact | REGULATION | Nov 10, 2026, 01:08 AM UTC
Australia PM Albanese: AI protections to be overseen by new dedicated AI safety regulator
L impact | REGULATION | Nov 10, 2026, 01:06 AM UTC
FDA Approves Sunharbo (Asundexian) 50 Mg Tablets
The FDA approved Bayer's Sunharbo (asundexian) 50 mg tablets to reduce stroke risk, described in the headline as the first Factor XIa inhibitor for this use.
M impact | REGULATION | Nov 09, 2026, 11:37 PM UTC
Trump Withdraws MacNeil’s Nomination For FTC Commissioner
L impact | REGULATION | Nov 09, 2026, 10:58 PM UTC
Bayer Wins US FDA Approval For Potential Blockbuster Stroke Drug
L impact | REGULATION | Nov 09, 2026, 10:42 PM UTC